Omnicell, Inc. (OMCL) fair value analysis

Nasdaq · Updated 2026-09-07

Omnicell, Inc. is a healthcare technology company that develops and provides automated medication and supply management solutions for healthcare facilities. The company operates globally, serving hospitals, pharmacies, and other healthcare organizations across multiple countries.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, OMCL is trading at a 10–25% discount to estimated fair value.

OMCL currently ranks #54 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $37.65
Sector: Healthcare
12-month range: $29.96–$48.70

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: Low
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The lower-middle quarter of its range

What our data shows for OMCL

Our model validated 17 trailing price-to-earnings windows for OMCL, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $29.96–$48.70.
The 14-day relative strength index sits at a neutral 41.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for OMCL
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent OMCL news

TickrTrends' derived news-sentiment signal for OMCL is currently leaning positive, computed from recent coverage.

OMCL Looks 9.4% Undervalued on GF Value™ (gurufocus.com, 2026-09-03)
TickrTrends take: TickrTrends currently rates OMCL as undervalued, which aligns with recent GF Value analysis suggesting approximately 9 percent undervaluation in the Healthcare sector. For investors focused on valuation metrics, the consistency between these independent assessments may warrant monitoring whether the market eventually reprices the stock toward its estimated fair value. The ongoing gap between current market price and calculated intrinsic value represents the key metric to track as fundamental conditions evolve.
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations (manilatimes.net, 2026-09-03)
TickrTrends take: Omnicell's integration of a DSCSA compliance solution with TraceLink addresses a regulatory requirement that hospitals must implement, potentially creating recurring revenue opportunities in the Healthcare sector. Given TickrTrends' undervalued assessment, investors should monitor whether this partnership translates into customer adoption metrics and contract value, as successful integration into hospital pharmacy workflows could strengthen the company's competitive positioning. The expansion of compliance-focused offerings may also indicate a shift toward higher-margin software and services revenue streams that could influence future earnings quality.
Omnicell Inc (OMCL) Stock Up 6.3% and Still Undervalued -- GF Score: 78/100 (gurufocus.com, 2026-09-01)
TickrTrends take: Omnicell's recent 6% stock price increase occurs within a context where TickrTrends' analysis indicates the company remains undervalued relative to its fundamentals. The GF Score of 78 out of 100 suggests solid operational and financial quality metrics that may not be fully reflected in the current market price. For investors focused on valuation, this combination of positive price momentum alongside an undervalued designation warrants monitoring whether the stock continues closing the gap to its intrinsic value or if healthcare sector dynamics create new opportunities.

What people are saying

Follow the OMCL conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — # OMCL Technical Summary TickrTrends' derived indicators for OMCL showed movement this week as the Relative Strength Index shifted from oversold into neutral territory. The company, which operates in the Healthcare sector, maintains an undervalued valuation verdict according to current analysis. This RSI transition suggests reduced selling pressure compared to the previous week's reading.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is OMCL stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), OMCL is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is OMCL's TickrTrends verdict?

OMCL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does OMCL compare to other Healthcare stocks?

OMCL ranks #54 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is OMCL overbought or oversold?

OMCL's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

OMCL vs A · OMCL vs BDX · OMCL vs ENSG · OMCL vs EW · OMCL vs HCA